There is the pharmaceutical composition of CEA resistance

There is the pharmaceutical composition of CEA resistance

  • CN 101,370,827 B
  • Filed: 12/21/2006
  • Issued: 10/14/2015
  • Est. Priority Date: 12/21/2005
  • Status: Active Grant
First Claim
Patent Images

1. be used for the treatment of the bispecific single-chain antibody of the epithelial tumor in people, it comprises(a) specific binding in first binding domains of people CD3, and(b) specific binding in second binding domains of people CEA,Wherein specific described second binding domains of people CEA is at least comprised-aminoacid sequence " DRGLRFYFDY ", SEQ ID NO.66, it corresponds to the Kabat position 95-102 of the CDR-H3 of mouse monoclonal antibody A5B7, and-CDR-H1 and CDR-H2, whereinA () described CDR-H1 is as shown in the aminoacid sequence " SYWMH " of SEQ ID NO:

  • 68, described CDR-H2 is as Suo Shi the aminoacid sequence " FIRNKANGGTTEYAASVKG " of SEQ ID NO;

    67 or as shown in the aminoacid sequence " FILNKANGGTTEYAASVKG " of SEQ ID NO;

    145;

    OrB () described CDR-H1 is as shown in the aminoacid sequence " TYAMH " of SEQ ID NO.70, described CDR-H2 is as shown in the aminoacid sequence " LISNDGSNKYYADSVKG " of SEQ ID NO.69;

    -CDR-L1 as shown in the aminoacid sequence " TLRRGINVGAYSIY " of SEQ ID NO;

    73;

    -CDR-L2 as shown in the aminoacid sequence " YKSDSDKQQGS " of SEQ ID NO;

    72;

    With-CDR-L3 as shown in the aminoacid sequence " MIWHSGASAV " of SEQ ID NO;

    71;

    Or, to the V district of specific described second binding domains of people CEA be wherein;

    the VH district that the aminoacid sequence shown in SEQ ID NO.56 forms and the VL district that the aminoacid sequence shown in SEQ ID NO.64 forms.

View all claims
    ×
    ×

    Thank you for your feedback

    ×
    ×